Valeant’s latest woe isn’t even financial
July 22, 2016 at 11:35 AM EDT
The FDA declined to approve the drug company’s glaucoma eye drop treatment because of manufacturing facility problems.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.